Accelerate Diagnostics

Accelerate Diagnostics Graham Number

Delisted

The Graham Number of Accelerate Diagnostics (AXDX) as of Nov 10, 2026 is 40.07 USD. In the previous year, Graham Number was 13.04 USD — a change of 207.36% (higher).

Graham Number

40.07USD

YoY

207.36%

Last updated:

Graham Number of Accelerate Diagnostics is 2024 40.07 USD. Graham Number of Accelerate Diagnostics was 2023 13.04 USD. It decreases by 207.36% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Accelerate Diagnostics Stock analysis

What does Accelerate Diagnostics do? Accelerate Diagnostics, Inc. generates revenue through its Accelerate Pheno system, an in vitro diagnostic platform that combines genotypic pathogen identification with phenotypic antibiotic susceptibility testing. The company sells the Accelerate Pheno system, including the fixed instrument and single-use test kits, to healthcare facilities for rapid diagnosis of serious infections. The Accelerate PhenoTest BC Kit specifically targets bacteremia and fungemia cases, providing ID and AST results directly from patient samples. Healthcare providers, particularly those treating life-threatening infections with high mortality risks, purchase these solutions to improve patient outcomes and reduce healthcare costs. The Accelerate Pheno system's walk-away automation feature reduces manual labor in laboratories, appealing to hospitals and clinical labs seeking efficiency. The company's focus on rapid diagnosis of serious infections aligns with healthcare institutions' needs for faster treatment decisions. By offering direct pathogen identification followed by targeted antibiotic testing, the system helps clinicians choose effective treatments more quickly, addressing high morbidity and mortality risks associated with bloodstream infections. Accelerate Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Accelerate Diagnostics stock

Graham Number of Accelerate Diagnostics is 40.07 USD in 2024.

On Eulerpool you can find the complete historical development of Graham Number Accelerate Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The Graham Number estimates the maximum fair price for a stock based on EPS and book value per share, following Benjamin Graham's value investing principles.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Accelerate Diagnostics

All Key Metrics — Accelerate Diagnostics